Anticoagulation for Stroke Prevention and Recovery After ICH (ASPIRE)
Conditions
Diseases of the Cardiovascular System | Diseases of the Nervous System
Phase III
Volunteers
Health Professionals
What is the purpose of this trial?
Brief Summary:
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF).
Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
- Ages18 years and older
- GenderBoth
- Trial withUniversity of Cincinnati
- Start Date06/19/2020
- End Date04/30/2024
I'm interested in volunteering
If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343
Principal Investigator
Sub-Investigators
- Last Updated11/15/2021
- Study HIC#2000026409